CompletedPhase 1NCT03776786
Safety and Tolerability of an Antibody Against Yellow Fever Virus (TY014) in Humans
Studying Yellow fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tysana Pte Ltd
- Principal Investigator
- Jenny Low, MBBSSingapore General Hospital
- Intervention
- TY014(biological)
- Enrollment
- 37 target
- Eligibility
- 21-50 years · All sexes
- Timeline
- 2018 – 2019
Study locations (1)
- SingHealth Investigational Medicine Unit, Singapore, Singapore
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03776786 on ClinicalTrials.govOther trials for Yellow fever
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06694766VAC-SIP-YF (Vaccination- Safety & Immunogenicity During Pregnancy- Yellow Fever)Institut Pasteur
- RECRUITINGNANCT06718127Description of the Immune Response to Yellow Fever VaccinationInstitut Pasteur
- RECRUITINGPHASE1, PHASE2NCT05859490Immunogenicity of Yellow Fever Vaccine 17D in Adults With Prior 17D VaccinationOregon Health and Science University
- ACTIVE NOT RECRUITINGNANCT05644145Immunogenicity of Yellow Fever Vaccine in a Pediatric Population Vaccinated at 12-23 Months of Age in ArgentinaMinistry of Public Health, Argentina
- ACTIVE NOT RECRUITINGPHASE2NCT05011123Study on an Investigational Yellow Fever Vaccine Compared With Stamaril in Adults in Europe and AsiaSanofi Pasteur, a Sanofi Company
- ACTIVE NOT RECRUITINGPHASE2NCT04942210Study on an Investigational Yellow Fever Vaccine Compared With YF-VAX in Adults in the USASanofi Pasteur, a Sanofi Company
- ACTIVE NOT RECRUITINGPHASE4NCT04083430Cytotoxicity of Yellow Fever Specific CD8 T Cells Following YF-17D VaccinationUniversity of Aarhus
- RECRUITINGPHASE4NCT03132311Immunogenicity and Safety of the Yellow Fever Vaccine in HIV Infected IndividualsOswaldo Cruz Foundation